Introduction
Apart from being effective antihypertensive agents, angiotensin I converting enzyme inhibitors have specific renal effects in patients with renal disease.
These effects include renal haemodynamic changes and a distinct fall in urinary protein excretion. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Because of these renal effects angiotensin converting enzyme inhibition may become a valuable pharmacological tool in preventing the progressive loss of renal function generally seen in patients with renal disease. However, whether inhibitors of the converting enzyme are indeed superior to other antihypertensive treatment regimens in this respect remains to be proved. One of the key questions is whether the alleged antiproteinuric (or protective) effect of angiotensin converting enzyme inhibitors is caused by the lowering of systemic blood pressure itself or whether it results from a specific action on renal function. The few studies that have addressed this question in diabetic4-6 and non-diabetic'"" renal disease generally indicated that angiotensin converting enzyme inhibitors are more effective in lowering proteinuria compared with conventional antihypertensive drugs. However, these studies had an open design. More importantly, many studies failed to obtain a similar blood pressure response with the drugs compared. In fact, angiotensin converting enzyme inhibitors seemed to induce a greater fall in blood pressure than the control drugs, leaving open the option that systemic blood pressure effects and not renal effects are the main mechanism by which angiotensin converting enzyme inhibitors reduce proteinuria.
To avoid this possible bias we studied the antiproteinuric and renal haemodynamic effects of the angiotensin converting enzyme inhibitor enalapril compared with the ,1 selective blocker atenolol in a randomised double blind design in 27 patients with proteinuria and non-diabetic renal disease.
Patients and methods
From a group of patients currently under study in a long term trial of the effects of antihypertensive treatment on the progression of loss of renal function in non-diabetic renal disease we selected the patients with proteinuria of more than 300 mg a day, measured on three consecutive visits in the pretreatment period (n=27). Other entry criteria were a creatinine clearance of 30-90 ml/min, a diastolic blood pressure >80 mm Hg, and no contraindications for treatment with a 13 blocker or an angiotensin converting enzyme inhibitor. The cause of the renal disease in these 27 patients (five women, 22 men; mean (SD) age 49 (13) years) was chronic glomerulonephritis (13 patients), chronic interstitial nephritis or pyelonephritis (seven), and nephrosclerosis (seven). The study was approved by the local medical ethics committee. Informed consent was obtained from each patient.
All patients adhered to a sodium restricted diet (50-80 mmol sodium/day). Protein intake was 0-8-1-0 g/kg body weight in the patients with a creatinine clearance of 60-90 ml/min and 0-6-0-8 g/kg body weight in those with a creatinine clearance of 30-60 ml/min. All antihypertensive drugs were withdrawn at least three weeks before active treatment started. In the pretreatment period the patients were seen every one to two weeks. Thereafter they were randomised to receive either enalapril 10 mg/day or atenolol 50 mg/day in a double blind fashion. Each patient was assigned an allocation number in chronological order with respect to the date of entry to the trial, which corresponded with the number on his or her treatment phial. The study treatment (enalapril or atenolol) had been randomly distributed beforehand among these numbers. 
Urinary protein excretion fell significantly from 2 -2 (1 -8) to 1 0 (I 3) g/day (p<0 001) in the enalapril group and not significantly, from 2-4 (1-9) to 2 1 (2-0) g/day in the atenolol group (fig 2, top) (fig 2, bottom) . Whereas the changes in blood pressure were never significantly different between both treatment groups proteinuria plotted either as absolute values or percentage values decreased significantly more in the enalapril group from week 4 onwards (p<0-02, p<0 05 respectively). The decrease in proteinuria in the patients treated with enalapril was associated with clear renal haemodynamic changes (table): effective renal plasma flow increased significantly (p<005); a significant, although numerically small, decrease in glomerular filtration rate occurred (p<0005); and as a result the filtration fraction appreciably decreased (p<O0OOl). Interestingly, in the patients treated with atenolol the filtration fraction also decreased (p<0005). Its decrease was, however, significantly greater in the enalapril group (p<002). Serum potassium concentration increased during treatment with enalapril (p<O0OOl) but it did not during atenolol treatment.
Serum urea concentration increased in the enalapril (p<O-OOl) and the atenolol (p<001) group. Sodium excretion was comparable in both groups during follow up and remained fairly stable during treatment (table) . The values indicated that the patients actually consumed slightly more salt than advised (1 10-1 20 instead of 50-80 mmol/day). Excretion of urea was also comparable in both groups, the value indicating a mean protein consumption of 55-75 g/day, corresponding to 0-7-ll g/kg bodyweight, which is also slightly higher than the dietary advice, and increasing slightly in both groups during treatment (p<OO1).
Discussion
This study shows that with a similar fall in blood pressure, urinary protein excretion decreases more with the angiotensin converting enzyme inhibitor enalapril than with the PI selective blocker atenolol in patients with non-diabetic renal disease. This suggests that the fall in urinary protein excretion during enalapril treatment is not due to lowering blood pressure itself but may be the consequence of the characteristic renal haemodynamic profile of this class of drugs.
To (14 7) 11-4 (3) (4) 3.3 (3.4) 105 (44) 15 (21) were commonly biased by the fact that blood pressure fell more in the group treated with the angiotensin converting enzyme inhibitor than in that treated with the other antihypertensive&agent.'" " Bjorck et al recently showed in diabetic patients that enalapril lowered proteinuria whereas metoprolol did not.4 Extrapolating these results in diabetic patients to patients with non-diabetic renal disease is, however, difficult. Owing to the afferent renal vasodilatation present in diabetic patients,'4 changes in blood pressure could more easily result in changes in intraglomerular capillary pressure, and thus in urinary protein excretion, than in non-diabetic patients.
As enalapril lowers proteinuria more effectively than atenolol it may be argued that the antiproteinuric effect is related to the specific renal haemodynamic effects of the angiotensin converting enzyme inhibitor. Animal studies have shown that inhibition of the converting enzyme results in a lowering of intraglomerular capillary pressure.'5 The fall in filtration fraction observed during angiotensin converting enzyme inhibition in humans can be used as an indirect measure for a fall in efferent arteriolar resistance and thus in intraglomerular capillary pressure.'6 Indeed those above mentioned comparative studies that also included renal haemodynamic data showed that the filtration fraction fell during treatment with the angiotensin converting enzyme inhibitor but not during the other antihypertensive treatment. '7 In that respect it is noteworthy that in this study atenolol, which is known to interfere in the renin-angiotensin system, did exert small but significant renal haemodynamic effects that showed a similar trend to those occurring with enalapril. During atenolol treatment the filtration fraction fell, although to a lesser extent than during enalapril treatment. This suggests that an antihypertensive drug may lower proteinuria only when it also lowers the filtration fraction.
Changes in dietary protein intake may also result in changes in proteinuria.'8 Excretion of urea (which reflects dietary protein intake) did not decrease during the 16 week follow up and, moreover, never differed between the two groups. The difference in the antiproteinuric effect between both groups therefore cannot be due to differences in protein intake.
No clinical side effects were observed in our patients.
Although pretreatment blood pressure was in the normotensive range in some of the patients, there were no complaints of hypotension with the doses used. Serum potassium concentration increased in the patients receiving enalapril; its increase could be managed adequately with dietary potassium restriction and did not prompt withdrawal of the angiotensin converting enzyme inhibitor. The followv up was too short to permit any conclusion about the possible effects of these treatments in preventing progressive decline in renal function. The more pronounced fall in proteinuria and in filtration fraction during enalapril treatment may, however, suggest that enalapril could afford more renal protection in the long term. Firstly, the degree of proteinuria is a prognostic variable for progressive deterioration of renal function.'9 Secondly, with filtration fraction as an indirect measure of intraglomerular capillary pressure a greater fall in this variable could also argue for a better prognosis for renal function.
We conclude that enalapril lowers urinary protein leakage more than atenolol in patients with nondiabetic renal disease. This suggests that the antiproteinuric effect during angiotensin converting enzyme inhibition is related more to the specific renal effects than to the antihypertensive effect itself.
